Peptide research, without the hype.

GLP-1 & metabolic peptides

The best-evidenced corner of the field. These are prescription medications with large randomized trials, real cardiovascular-outcome data, and well-characterized side effects — plus the investigational next generation.

Repair & recovery peptides

The most hyped category online and the thinnest in human trials. These guides lay out exactly what the preclinical work shows and where the clinical evidence stops.

Growth-hormone axis peptides

Secretagogues and GHRH analogs sold widely by anti-aging clinics. One of them is FDA approved for a narrow indication; the rest are not approved for anything.

Brain, longevity & cellular peptides

Nootropic and anti-aging compounds, several approved in Russia but nowhere else, and several whose entire reputation rests on cell-line work.

Other high-demand peptides

Three compounds that generate enormous search volume for very different reasons — one approved by the FDA, one immunomodulator approved abroad, and one with a documented harm record.

30 more peptide research guides

The expanded library covers established peptide medicines and heavily searched experimental compounds. Each page separates approved use, human research, preclinical evidence, and unsupported marketing.

Metabolic peptide medicines

Established and emerging peptide medicines for diabetes, rare genetic obesity, and appetite regulation, separated by indication and evidence strength.

Growth and performance peptides

Frequently marketed GH-axis and muscle-growth compounds, with a hard line between endocrine pharmacology and unsupported performance claims.

Brain and longevity peptides

Neuroactive and mitochondrial peptides whose reputations often run far ahead of controlled human evidence.

Immune and repair peptides

Endogenous immune-signaling peptides with convincing laboratory biology but limited evidence as stand-alone human therapies.

Reproductive hormone peptides

Peptides that act on the hypothalamic-pituitary-gonadal axis, from experimental kisspeptin protocols to established GnRH agonists.

Gastrointestinal peptide medicines

Peptide medicines that act locally in the gut or support intestinal adaptation, with randomized trials and narrow approved indications.

Specialist peptide medicines

Approved peptide therapies used in porphyria, neuroendocrine disease, osteoporosis, and severe chronic pain.

Head-to-head comparisons

The direct comparisons people search before a clinic appointment — built on head-to-head trials where they exist, and explicit about when they do not.

Practical guides

The questions that come after the research: what the law says, why clinicians care about site rotation, and how to keep a record you can actually hand to a doctor.

Landmark clinical trials

Standalone breakdowns of the trials the drug guides keep citing — design, population, primary and secondary results, and limitations, each with the PubMed record and ClinicalTrials.gov registration.

How the drugs work: mechanisms

The receptors and pathways every drug guide refers back to — what they are, what activating them does, and why the newer dual and triple agonists were designed the way they are.

Conditions these drugs treat

The diseases behind the prescriptions — what they are, and what the trials actually showed for each.

Research glossary

The terms that decide what a trial number actually means — defined in plain English so you can read the studies, not just the headlines.